Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Butyrylcholinesterase deficiency

Endocrine, Nutritional and Metabolic Diseases

Butyrylcholinesterase deficiency (also known as pseudocholinesterase deficiency, and succinylcholine sensitivity) is an autosomal recessive inherited blood plasma enzyme abnormality in which the body's production of butyrylcholinesterase (BChE) is impaired. People who have this abnormality may be sensitive to certain anesthetic drugs, including the muscle relaxants succinylcholine and mivacurium as well as other ester local anesthetics.

Facts
Classification
Body System
Endocrine System 1
ICD-10 Chapter
IV: Endocrine, Nutritional and Metabolic Diseases 1
Communicable or Non-communicable
Non-Communicable 2
Transmission Route
Non-Transmissible 3
Causative Agent
Causative Agent (category)
Genetic / Hereditary 3
Sources
1. Wikipedia: ICD-10
WikipediaList of chapters, Chapter IV
Quote, List of chapters, Chapter IV
Endocrine, nutritional and metabolic diseases
View the Source
2. World Health Organization: Noncommunicable diseases (fact sheet)
World Health OrganizationMain Types section
Quote, Main Types section
The main types of NCDs are cardiovascular diseases (such as heart attacks and stroke), cancers, chronic respiratory diseases (such as chronic obstructive pulmonary disease and asthma) and diabetes.
View the Source
3. Butyrylcholinesterase deficiency (Wikipedia)
  • lead sentence 1
    Butyrylcholinesterase deficiency (also known as pseudocholinesterase deficiency, and Succinylcholine Sensitivity is an autosomal recessive inherited blood plasma enzyme abnormality in which the body's production of butyrylcholinesterase (BChE) is impaired.
  • Lead section, transmission-route statement
    Butyrylcholinesterase deficiency (also known as pseudocholinesterase deficiency, and Succinylcholine Sensitivity is an autosomal recessive inherited blood plasma enzyme abnormality in which the body's production of butyrylcholinesterase (BChE) is impaired.
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.